Fig. 3From: Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong KongDSA Results for Ceritinib vs. Crizotinib. AE, adverse event, ICER, incremental cost-effectiveness ratio; PFS, progression-free survival; OS, overall survivalBack to article page